Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optic pathway gliomas.

Christopher D Jahraus1, Nancy J Tarbell

  • 1Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA. cjahraus@uabmc.edu

Pediatric Blood & Cancer
|January 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making Sense of the 2026 Centers for Medicare and Medicaid Services (CMS) Radiation Oncology Treatment Delivery Codes: Historical Context and Practical Applications for Clinicians.

Cureus·2026
Same author

Current Practices in, Reimbursement Opinions About, and Clinical Indications of Adaptive Radiation Therapy: Results From the American College of Radiation Oncology Survey.

Cureus·2025
Same author

Quality of life in pediatric patients treated with adjuvant proton radiation for craniopharyngiomas.

Journal of neuro-oncology·2025
Same author

General Consensus on Implementing an Episode-Based Payment Model: Results From the American College of Radiation Oncology (ACRO) Payment Reform Survey.

Cureus·2025
Same author

Self-Reported Health Status Survey Creation and Distribution Outcomes in a Large Cohort of Pediatric Oncology Patients Treated with Proton Radiation Therapy.

Advances in radiation oncology·2025
Same author

Medicare Physician Fee Schedule.

JAMA·2023
Same journal

Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.

Pediatric blood & cancer·2026
Same journal

Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.

Pediatric blood & cancer·2026
Same journal

The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.

Pediatric blood & cancer·2026
Same journal

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric blood & cancer·2026
Same journal

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same journal

Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
See all related articles

Optic pathway gliomas are common pediatric brain tumors. While chemotherapy is now first-line, its frequent failure necessitates careful management selection to optimize outcomes for children.

Area of Science:

  • Pediatric neuro-oncology
  • Ophthalmology
  • Neurosurgery

Background:

  • Optic pathway gliomas (OPGs) constitute about 5% of pediatric intracranial tumors.
  • Most OPGs are low-grade astrocytomas with unpredictable clinical behavior.
  • Management is complex due to frequent occurrence in infants and young children.

Purpose of the Study:

  • To review the epidemiology, pathology, and therapeutic interventions for OPGs.
  • To discuss outcomes and treatment sequelae associated with OPG management.
  • To highlight the need for careful therapy selection in pediatric OPGs.

Main Methods:

  • Literature review of OPGs.
  • Analysis of historical and current treatment strategies.
  • Synthesis of data on clinical course, outcomes, and sequelae.

Related Experiment Videos

Main Results:

  • Chemotherapy has become the first-line treatment, largely replacing surgery and radiotherapy.
  • Chemotherapy often fails, delaying definitive treatment and potentially impacting neurodevelopment.
  • Careful selection of therapy is crucial given the generally favorable prognosis.

Conclusions:

  • Optimal management of pediatric optic pathway gliomas remains debated.
  • Current treatment paradigms require careful consideration of efficacy and long-term sequelae.
  • Further research is needed to refine therapeutic strategies for OPGs.